Table 3.
Constituent ratio of yearly data of AEs related to Alprazolam.
| Factors | Number of events (%) |
|---|---|
| Gender | |
| Female | 13,326 (56.53) |
| Male | 8450 (35.84) |
| Unknown | 1799 (7.63) |
| Age | |
| < 18 | 704 (2.99) |
| 18–45 | 6569 (27.86) |
| 45–65 | 5937 (25.18) |
| 65–75 | 1911 (8.11) |
| ≥ 75 | 1853 (7.86) |
| Unknown | 6601 (28.00) |
| Reporter | |
| Consumer | 8339 (35.37) |
| Pharmacist | 4658 (19.76) |
| Physician | 7061 (29.95) |
| Other health professionals | 2971 (12.60) |
| Unknown | 470 (1.99) |
| Lawyer | 76 (0.32) |
| Reported countries | |
| United States | 12,833 (54.43) |
| France | 4377 (18.57) |
| Italy | 2347 (9.96) |
| Brazil | 752 (3.19) |
| Japan | 436 (1.85) |
| Report year | |
| 2004 | 175 (0.74) |
| 2005 | 212 (0.90) |
| 2006 | 195 (0.83) |
| 2007 | 287 (1.22) |
| 2008 | 278 (1.18) |
| 2009 | 271 (1.15) |
| 2010 | 630 (2.67) |
| 2011 | 434 (1.84) |
| 2012 | 535 (2.27) |
| 2013 | 551 (2.34) |
| 2014 | 931 (3.95) |
| 2015 | 2114 (8.97) |
| 2016 | 1764 (7.48) |
| 2017 | 1639 (6.95) |
| 2018 | 2480 (10.52) |
| 2019 | 3268 (13.86) |
| 2020 | 3245 (13.76) |
| 2021 | 1789 (7.59) |
| 2022 | 1795 (7.61) |
| 2023 | 982 (4.17) |
| Serious outcomes | |
| Death | 5153 (21.86) |
| Disability | 451 (1.91) |
| Hospitalization—initial or prolonged | 7298 (30.96) |
| Life-Threatening | 1158 (4.91) |
| Adverse event occurrence time—medication date (days) | |
| 0–30 | 4158 (17.64) |
| 31–60 | 92 (0.39) |
| 61–90 | 77 (0.33) |
| 91–120 | 46 (0.20) |
| 121–150 | 34 (0.14) |
| 151–180 | 35 (0.15) |
| 181–360 | 106 (0.45) |
| > 360 | 482 (2.04) |